Arbutus Biopharma Corp (I9DN)

2.890 -0.018 (-0.62%)
Closed EUR Disclaimer

Arbutus Biopharma Corp Company Profile

Equity Type
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Contact Information
Warminster,18974 United States
267 469 0914
Top Executives
Frank M. Torti 42 2018 Independent Chairman of the Board of Directors
Kyong-Mi Chang 0 0000 Member of Scientific Advisory Board
Ulrike Protzer 0 0000 Member of Scientific Advisory Board
Adrian Di Bisceglie 0 0000 Member of Scientific Advisory Board
Keith S. Manchester 56 2015 Independent Non-Executive Director
William T. Symonds 56 2015 Chairman of Scientific Advisory Board
Fabien Zoulim 0 0000 Member of Scientific Advisory Board
James R. Meyers 59 2018 Independent Director
Daniel D. Burgess 62 2017 Independent Director
Charles M. Rice 0 0000 Member of Scientific Advisory Board
Scott A. Biller 68 0000 Member of Scientific Advisory Board
Richard C. Henriques 68 2014 Independent Non-Executive Director
Melissa V. Rewolinski 53 2023 Independent Director
Michael J. McElhaugh 49 2018 Co-Founder, Interim President, CEO & Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.